Teva Returns to CIIE, Partners with Local Enterprises to Accelerate Innovative Drug Access in China

Today, Teva Pharmaceutical Industries, a global leading biopharmaceutical enterprise, is participating in the 6th China International Import Expo (CIIE). Appearing once again at booth A1-03 in Hall 7.2 of the Medical Devices and Healthcare Products Exhibition Area, Teva will"Link Multiple Parties, Foster Innovation, Benefit China"For a brand-new theme, showcasing multiple star products covering various fields in an all-round way, and joining hands with multiple local partners.Further strengthen cooperation in China, deeply implement the "In China, For China" strategy, and write a new chapter for a healthy future with open innovation.

“The CIIE is not only a global business card for China's high-level opening to the outside world, but also an invaluable platform for Teva to deepen its presence in the Chinese market.。Last year, Teva Pharmaceutical Industries made its debut at the CIIE and benefited greatly from the event's powerful spillover effects.

Huang Diren

General Manager of Teva Greater China Region

Teva Greater China General Manager Huang Diran"This year, Teva Pharmaceutical Industries Ltd. returns to the CIIE. While showcasing our innovative products, we look forward to seizing the opportunities presented by the CIIE, deepening exchanges and cooperation with local partners, and continuously enhancing the accessibility and affordability of high-quality medicines for Chinese patients. We aim to contribute to the realization of the grand blueprint of 'Healthy China 2030'."

Star Exhibits Gather

Meeting the Diverse Health Needs of the Chinese People

Since Teva entered the Chinese market, it has always focused on the health needs of the Chinese people, striving to introduce high-quality products in underserved therapeutic areas. At this year's CIIE, Teva will highlight two key products in China."First Exhibition, First Debut" Products: Innovative Migraine Drug Remanezumab and Consumer Healthcare Product Sudocrem^®。

The innovative migraine drug Remanezumab can be used for preventive treatment of migraines in adult patients who experience migraines on at least 4 days per month, and is expected to help improve the quality of life for hundreds of millions of migraine patients in China. Thanks to the "Hong Kong-Macao Drug and Medical Device Interim Scheme," Remanezumab has been authorized by the Guangdong Provincial Drug Administration for use in the Guangdong-Hong Kong-Macao Greater Bay Area.

Sudocrem, the classic diaper rash cream from Ireland^®It is the first health consumer product introduced by Teva to China, to meet the increasingly diverse health consumption needs of the Chinese people. Sudocrem^®Suitable for treating various skin problems, it is also a staple product for skin management in households worldwide.

In addition, three star products - Triptorelin^®, Antai Tan^®Hecenda^®Will also "return" to the CIIE stage. Among them, Teva's classic drug for multiple sclerosis, Copaxone, which debuted at the CIIE last year.^®(Glatiramer Acetate Injection) has benefited from the powerful spillover effects of the CIIE,Achieving "展品变商品", it was officially approved in June this year, accelerating benefits for patients in China.

Expand Local Network

Accelerate Innovation Cooperation to the Fullest Extent

At this CIIE, Teva will actively leverage the strong "magnetic field" of the CIIE to connect with more like-minded partners in the medical ecosystem, jointly contributing to the transformation and upgrading of China's healthcare system.

Teva will partner with multiple local partners, integrating advantages in channel networks, supply chain systems, and other aspects to expand the nationwide coverage of medicines in China and enhance patient access to Teva's high-quality medications. Additionally, Teva will leverage the strengths of local partners' registration, market access, and commercialization teams.To jointly identify, develop, and commercialize Teva's globally marketed products in China through diversified cooperation models, meeting the diverse health needs of the Chinese people.

Innovation as the Key

Opening a New Chapter in a Healthy Future

The large display device of the gene helix structure is the "highlight" of Teva's exhibition area this time. The helical lines extend upward, symbolizing Teva's innovative gene that has continuously pursued breakthroughs since its establishment.

In May this year, Teva released its new global strategy, Pivot to Growth, with innovation as a key pillar. Teva will integrate its long-standing leading advantages in active pharmaceutical ingredients and generic drugs with its knowledge in innovative drug development through an integrated drug R&D model. Focusing on the two therapeutic areas of the central nervous system and immunology, Teva aims to provide high-quality innovative treatment solutions for patients worldwide.As one of Teva's key regions globally, Teva will also start from the urgent needs of Chinese patients, accelerate the introduction of its innovative drug pipeline to China, and diversify the medication options for Chinese patients.

The CIIE not only presses the "accelerator button" for Teva to introduce high-quality global medicines, transforming "exhibits into products," but also creates a platform for cooperation and exchange to expand Teva's local "circle of friends" in China.Riding the wave of the CIIE, Teva will continue to invest heavily in the Chinese market, aligning with China's high-quality development. It will significantly enhance the accessibility and affordability of high-quality medicines for Chinese patients, fulfilling its new mission of "Going all out to build a healthy future together."